Incyte Genomics and American Home Products Form Strategic Partnership in Gene Sequencing and Drug Discovery

Strategic Insights -

Incyte Genomics, a leading genomic information company, and American Home Products, a major research-oriented pharmaceutical company, announced a partnership that grants AHP access to Incyte's suite of gene sequence databases, including LifeSeq(R) Gold, for use in drug discovery and development. This partnership highlights the significance of transcribed gene sequence data in the development of safer, more effective drugs and showcases the importance of genomic technologies in the pharmaceutical industry. The collaboration will enable AHP researchers to access Incyte's extensive gene patent portfolio, containing over 500 issued and allowed patents on full-length human genes, as well as its ZooSeq(TM) animal model database and the PathoSeq(TM) microbial sequence database.

Key Takeaways:

  • Incyte Genomics and American Home Products have formed a strategic partnership in gene sequencing and drug discovery, with AHP gaining access to Incyte's suite of gene sequence databases, including LifeSeq(R) Gold.
  • LifeSeq Gold contains over 100,000 transcribed genes, including approximately 60,000 novel genes, and provides a unique view of the entire human genome.
  • Access to LifeSeq Gold also includes access to high-quality sequence-verified cDNA clones, which AHP researchers can obtain to conduct further research in the lab.
  • The partnership will enable AHP researchers to utilize Incyte's genomic databases and technologies for deciphering the complexity of the human genome and applying that knowledge to drug discovery and development.
  • Incyte could receive future milestone payments and royalties on sales of products developed with Incyte technology and database information.
  • American Home Products is one of the world's largest research-based pharmaceutical and health care products companies, with a significant presence in the discovery, development, manufacturing, and marketing of prescription drugs and over-the-counter medications.
  • Incyte Genomics is the leading provider of integrated genomic technologies designed to aid in the understanding of the molecular basis of disease, with a platform of genomic databases, data management software, microarray-based gene expression services, related reagents, and services.

Statistics:

  • LifeSeq Gold contains over 100,000 transcribed genes.
  • Approximately 60,000 of these genes are novel.
  • The database contains more than 100,000 transcribed, or expressed, genes.
  • Incyte's gene patent portfolio contains over 500 issued and allowed patents on full-length human genes.

Sources:

  • Incyte Genomics press release, July 17 (PRNewswire)
  • American Home Products Corporation website, www.ahp.com
  • Incyte Genomics website, www.incyte.com
  • SEC reports, including Incyte's Quarterly Report on Form 10-Q for the quarter ended March 31, 2000.